CONNAUGHT HOUSE, DUBLIN 4, L2
Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Shareholders Approve Increase of 5.9M Shares in 2018 Stock Option Plan
Announces Positive Topline Results From REVITALYZSM Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Reports First Quarter 2026 Financial Results
Amended material disclosure
Annual Report to Security Holders
Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
Announces CEO Succession Plan
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-8 POS